Overview

Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

There is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients with advanced gastric cancer. XP is a new standard of care in advanced gastric cancer (AGC) and vorinostat is a novel targeted agent that prevents tumor cell proliferation, survival and angiogenesis through histone deacetylase inhibition.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Asan Medical Center

Treatments:

Capecitabine
Cisplatin
Histone Deacetylase Inhibitors
Vorinostat